statistiche ricercatore

Continente	#
EU - Europa	783
NA - Nord America	623
AS - Asia	398
SA - Sud America	66
AF - Africa	11
OC - Oceania	2
Continente sconosciuto - Info sul continente non disponibili	1
Totale	1.884

Nazione	#
US - Stati Uniti d'America	608
DE - Germania	282
SG - Singapore	175
IT - Italia	167
SE - Svezia	94
CN - Cina	80
FR - Francia	62
BR - Brasile	52
GB - Regno Unito	43
UA - Ucraina	39
JP - Giappone	36
VN - Vietnam	36
IN - India	22
PL - Polonia	19
IE - Irlanda	16
RU - Federazione Russa	13
HK - Hong Kong	12
CA - Canada	11
FI - Finlandia	11
NL - Olanda	11
ID - Indonesia	10
BE - Belgio	7
IQ - Iraq	7
MA - Marocco	6
AR - Argentina	5
HU - Ungheria	5
BD - Bangladesh	4
VE - Venezuela	4
JO - Giordania	3
LV - Lettonia	3
ZA - Sudafrica	3
AT - Austria	2
CO - Colombia	2
EC - Ecuador	2
KR - Corea	2
LT - Lituania	2
MX - Messico	2
NZ - Nuova Zelanda	2
A2 - ???statistics.table.value.countryCode.A2???	1
AZ - Azerbaigian	1
BY - Bielorussia	1
BZ - Belize	1
CI - Costa d'Avorio	1
CR - Costa Rica	1
CV - Capo Verde	1
CZ - Repubblica Ceca	1
ES - Italia	1
IL - Israele	1
KG - Kirghizistan	1
LK - Sri Lanka	1
LU - Lussemburgo	1
MM - Myanmar	1
MY - Malesia	1
PH - Filippine	1
PT - Portogallo	1
PY - Paraguay	1
RO - Romania	1
RS - Serbia	1
SA - Arabia Saudita	1
TR - Turchia	1
TW - Taiwan	1
UZ - Uzbekistan	1
Totale	1.884

Nome	#
High intensity focused ultrasound (HIFU) in prostate cancer: today’s outcomes and tomorrow’s perspectives	357
Le infezioni delle vie urinarie	251
Do testis germinal tumours express PTTG (Pituitary Transforminf Tumour Gene)	237
The occult urothelial cancer	199
Bladder and prostate metastasis from small cell lung cancer: a rare entity	165
Imaging in prostate cancer staging: present role e future perspectives	153
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "bCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes	149
Local relapse of prostate cancer after primary definitive treatment: the management	143
High intensity focused ultrasound as first line salvage therapy in prostate cancer local relapse after radical prostatectomy: 4-year follow-up outcomes	139
Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer	115
Totale	1.908

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	22	0	0	0	0	0	0	0	0	0	0	19	3
2021/2022	157	12	8	2	12	9	3	18	21	15	11	18	28
2022/2023	297	42	40	22	49	13	37	15	23	29	6	12	9
2023/2024	126	6	26	4	18	10	15	4	12	2	2	14	13
2024/2025	239	11	12	22	12	27	35	2	12	15	24	37	30
2025/2026	453	74	5	16	49	83	22	116	28	26	33	1	0
Totale													1.908

IRIS UniCatt